Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab with neoadjuvant FEC/EC-paclitaxel in HER2-negative inflammatory breast cancer
2016-001868-11Phase 2Active
- Sponsor
- Institut Paoli-Calmettes
- Start
- Sep 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of pembrolizumab in inflammatory breast cancer (IBC) and breast cancer (2 arms), sponsored by Institut Paoli-Calmettes. Primary endpoint: Pathological complete response rate. Started Sep 2017; status: active.
02
Drugs
03
Conditions
inflammatory breast cancer (IBC)breast cancer
Beyond the preview
Go deeper on 2016-001868-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-001868-11.